Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
复制标题
DOI：
10.1038/87887
复制
发表时间：
2001-05-01
期刊：
影响因子：
82.9
通讯作者：
Gomariz, RP
中科院分区：
文献类型：
--
作者：
Delgado, M;Abad, C;Gomariz, RP
风湿性关节炎（RA）是一种病因不明的慢性自身免疫性疾病，其特征在于关节慢性炎症和随后的软骨和骨破坏。我们在这里描述了一种新的治疗关节炎的策略：神经肽血管活性肠肽（VIP）的管理。VIP治疗显著降低了实验模型中关节炎的发病率和严重程度，完全消除了关节肿胀和软骨和骨的破坏。VIP的治疗效果与疾病的炎症和自身免疫成分的下调有关。我们的数据表明VIP是开发RA治疗的可行候选药物。
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease of unknown etiology, characterized by chronic inflammation in the joints and subsequent destruction of the cartilage and bone. We describe here a new strategy for the treatment of arthritis: administration of the neuropeptide vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone. The therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease. Our data indicate VIP as a viable candidate for the development of treatments for RA.